Key hospital-infections markets set to grow to over $4 billion in 2020; report
Despite market constraints that include intensified competition, generic erosion and an increasingly stringent regulatory and reimbursement environment, the drug market for key hospital-treated infections that are of high interest to drug developers - most notably nosocomial pneumonia, bloodstream infections, skin and skin structure/surgical site infections and urinary tract infections - will increase from $3.3 billion in 2010 to just over $4 billion in 2020 in the USA, France, Germany, Italy, Spain, the UK and Japan.
The uptake of eight new therapies, as well as Forest/AstraZeneca/Dainippon Sumitomo’s anti-MRSA cephalosporin Teflaro (ceftaroline fosamil; which launched in the USA in 2011), will help offset sales losses and will account for 3%of major-market sales in 2020, according to a new report from advisory firm Decision Resources.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze